Biotech Gainers: Geron Corporation (NASDAQ:GERN), Can-Fite BioPharma (NYSEMKT:CANF), Galena Biopharma (NASDAQ:GALE), Exact Sciences Corporation (NASDAQ:EXAS), Progenics Pharmaceuticals (NASDAQ:PGNX)


Geron Corporation (NASDAQ:GERN) on Nov. 13 announced that the company has entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc. (“Janssen”) to develop and commercialize, imetelstat, Geron`s telomerase inhibitor product candidate, for oncology, including hematologic malignancies, and other human therapeutics uses. Imetelstat is a modified oligonucleotide that is currently in early phase clinical development for myelofibrosis (MF) and may have activity in other hematologic myeloid malignancies such as myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). Geron Corporation (NASDAQ:GERN) in last trading activity increased 13.85% to close at $3.70. Company weekly performance is 34.06% while its quarterly performance stands at 56.78%. Geron Corporation (NASDAQ:GERN) is -43.44% away from its 52 week high.

Wainwright initiated coverage on shares of Can Fite Biopharma Ltd (NYSEMKT:CANF) in a research report released on Tuesday morning, TheFlyOnTheWall.com reports. The firm issued a buy rating and a $7.00 price objective on the stock. On last trading day Can-Fite BioPharma Ltd. (NYSEMKT:CANF) increased 20.00% to close at $4.80. Its volatility for the week is 33.77% while volatility for the month is 12.41%. Can-Fite BioPharma Ltd. (NYSEMKT:CANF) monthly performance is 64.95%.

Galena Biopharma Inc. (NASDAQ:GALE) announced the execution of a purchase agreement for up to $55.0 million with Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor. On last trading day Galena Biopharma, Inc. (NASDAQ:GALE) increased 11.29% to close at $2.07. Its volatility for the week is 5.48% while volatility for the month is 6.59%. GALE’s EPS growth for past 5 years was 4.90%. Galena Biopharma, Inc. (NASDAQ:GALE) monthly performance is 9.52%.

EXACT Sciences Corporation (NASDAQ:EXAS) Insider Graham Peter Lidgard unloaded 8,015 shares of the company’s stock on the open market in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $24.68, for a total value of $197,810.20. Following the transaction, the insider now directly owns 184,768 shares in the company, valued at approximately $4,560,074. Exact Sciences Corporation (NASDAQ:EXAS) has 1.40% insider ownership while its institutional ownership stands at 95.00%. In last trading activity company’s stock closed at $23.98.

Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) EVP Robert J. Israel sold 10,000 shares of the stock on the open market in a transaction that occurred on Thursday, November 13th. The shares were sold at an average price of $6.83, for a total value of $68,300.00. Following the completion of the transaction, the executive vice president now directly owns 35,050 shares of the company’s stock, valued at approximately $239,392. On Friday shares of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) closed at $6.77. Company’s sales growth for last 5 years was -34.90% and EPS growth for next 5 years is recorded as 25.00%.


Leave a Reply

Your email address will not be published. Required fields are marked *